PLYX
Polaryx Therapeutics, Inc. Common Stock
NASDAQ: PLYX · HEALTHCARE · BIOTECHNOLOGY
$5.22
-7.28% today
Updated 2026-04-29
Market cap
$247.13M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.19
Dividend yield
—
52W range
$2 – $49
Volume
1.1M
WallStSmart proprietary scores
16
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C5.0
Quality
C+3.0
Profitability
D5.0
Valuation
C+—/9
Piotroski F-Score
—
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →206 stocks currently score above 75
Price targets
Analyst target
$10.00
+91.57%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
1 Strong Buy0 Buy0 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
Insufficient data
Risks
- Thin margins at 0.00%
- Negative free cash flow $-1.49M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-3.78M | $-30.36M | $-8.98M | $-1.50M |
| EPS | — | — | — | $-0.19 |
| Free cash flow | $-173000.00 | $-2.57M | $-3.94M | $-1.49M |
| Profit margin | — | — | — | — |
Peer comparison
Smart narrative
Polaryx Therapeutics, Inc. Common Stock trades at $5.22. Our Smart Value Score of 16/100 indicates the stock is weak.
Frequently asked questions
What is Polaryx Therapeutics, Inc. Common Stock's stock price?
Polaryx Therapeutics, Inc. Common Stock (PLYX) trades at $5.22.
Is Polaryx Therapeutics, Inc. Common Stock overvalued?
Smart Value Score 16/100 (Grade F, Strong Sell).
What is the price target of Polaryx Therapeutics, Inc. Common Stock (PLYX)?
The analyst target price is $10.00, representing +91.6% upside from the current price of $5.22.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-193.70%
Beta—
50D MA$5.08
200D MA$6.26
Shares out0.05B
Float0.00B
Short ratio—
Avg volume1.1M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—